It is modified to selectively replicate in p16/Rb-defective cells, which include most human cancer cells. In addition,<unk>  codes for the granulocyte–macrophage colony-stimulating factor (GM-CSF), a potent immunostimulatory molecule. The therapeutic potential of<unk> ytic virotherapy is not a simple consequence of the cytopathic effect but strongly relies on the induction of an endogenous immune response against transformed cells. Superior anticancer effects have been observed when<unk> ytic viruses are engineered to express (or be co-administered with) immunostimulatory molecules such as GM-CSF.
ONCOS-102
CARB-X
MCN
SCALPEL
BGR-34
BIM-1
COVAX-19
CURB-65